On November 23, 2021 Exscientia (Nasdaq: EXAI) reported that Andrew Hopkins, DPhil., Exscientia’s founder and CEO, Ben Taylor, CFO & Chief Strategy Officer, and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT) (Press release, Exscientia, NOV 23, 2021, View Source [SID1234595989]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Company’s website, under the "Investors & Media" section at investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation.

On November 23, 2021 Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, reported that Daniel Vitt, Ph.D., Chief Executive Officer and President, will participate in a fireside chat at the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference, taking place November 29-December 2, 2021 (Press release, Immunic, NOV 23, 2021, View Source;co-33rd-annual-virtual-healthcare-conference-301430529.html [SID1234596006]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pre-recorded presentation is available for registered attendees via the Piper Sandler conference site from Monday, November 22 to Thursday, December 2 and on the "Events and Presentations" section of Immunic’s website at: View Source An archived replay will be available on the company’s website for a period of 90 days after the conference.

On November 23, 2021 CureLab Oncology reported that it has been granted a patent protection in India for anti-cancer application of our lead product, Elenagen (Press release, CureLab Oncology, NOV 23, 2021, View Source [SID1234596166]). This brings the total number of countries in which CureLab Oncology has patent protection to over 20 — you can see the complete list here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Because of its huge population and established biotech expertise, we see enormous potential in the Indian market for CureLab’s therapies. According to INVEST INDIA, India is among the top 12 destinations for biotechnology in the world, with an approximately 3% share of the global biotechnology industry. In aggregate, the biotech sector is a key contributor to India’s vision of reaching a $5 trillion economy by 2024.

The rising incidence of cancer in India is expected to boost the immuno-oncology drugs market expansion across the country. According to the Indian Council of Medical Research (ICMR) – National Institute of Cancer Prevention and Research (NICPR), incidence of breast cancer is 25.8 per 100,000 women in 2018 and is expected to reach 35 per 100,000 women in 2026.

The India immuno-oncology drugs market was valued at $172.8 million in 2018 and is expected to experience a CAGR of 13.1% from 2018 through 2026.
Like any promising biotech company, we view a comprehensive, global approach to IP protection as immensely important to our strategic business plan. One reason is that annual industrial biopharmaceutical R&D spending has declined over the past decade, with large pharmaceuticals instead focusing on partnership and acquisition strategies with biotech startups whose technology shows great promise.

As we expand our patent portfolio and geographic operations, we will adapt our IP strategy to maximize the value of the company.

On November 23, 2021 GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) (Press release, GlycoMimetics, NOV 23, 2021, View Source [SID1234595972]). Apollomics’ Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study. The Phase 3 clinical trial is part of a randomized, double-blind, placebo controlled, bridging study program that will evaluate the efficacy of uproleselan in combination with chemotherapy, compared to chemotherapy alone, for treating relapsed/refractory AML, in Chinese patients. The trial will enroll approximately 140 adult patients with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Dosing of the first patient in this Phase 3 clinical trial in Greater China is a significant accomplishment for Apollomics and comes quickly on the heels of our recent completion of enrollment in our own pivotal Phase 3 trial evaluating uproleselan in addition to a standard chemotherapy regimen in patients with relapsed/refractory AML," commented Harout Semerjian, GlycoMimetics Chief Executive Officer.

The primary endpoint for the Apollomics Phase 3 trial is overall survival. Secondary outcome measures include the rate and duration of remission, and whether uproleselan could reduce the rate of oral mucositis, a chemotherapy-related side effect. Apollomics expects to conduct this study at approximately 20 blood cancer clinical research centers across China. Additional information on the Phase 3 trial can be found on clinicaltrials.gov (NCT05054543)

On November 23, 2021 Hologic, Inc. (Nasdaq: HOLX) reported that it will showcase its extensive portfolio of breast and skeletal health products, including screening and diagnostics solutions, breast biopsy, and breast cancer treatment and monitoring solutions, at the 107th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 28 to Dec. 2 (Press release, Hologic, NOV 23, 2021, View Source [SID1234595990]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On-site at McCormick Place, in the South Hall in Booth #2511, Hologic will offer attendees opportunities to engage with products, including the Dimensions mammography portfolio, Mach ultrasound systems, and a full suite of breast biopsy and surgery solutions. Additionally, the Company will host a series of both CME and non-CME accredited medical education symposiums and lunch-and-learn sessions, accessible to attendees on-site and from remote locations.

"We’re excited to provide our attendees hands-on experiences with our category-leading innovations, both in our booth and during our medical sessions, as we explore the future of breast health at RSNA 2021," said Jennifer Meade, Hologic’s Division President, Breast and Skeletal Health Solutions. "Our commitment to delivering clinically proven solutions across the continuum of care to improve outcomes, reduce costs and increase patient satisfaction remains steadfast, and we’re ready to bring that commitment to life through our comprehensive programming at this year’s meeting both in-person and virtually."

Medical sessions and symposia taking place throughout the event include:

Clinical Perspective: 3D-Guided Breast Biopsies and Real-Time Specimen Imaging
Harriet B. Borofsky, M.D.
Sunday, Nov. 28: 11:45am – 12:45pm CT
Artificial Intelligence in Breast Imaging (CME)
Sarah (Sally) Friedewald, M.D., FACR
Monday, Nov. 29: 8:00 – 9:00am CT
Options and Tips in Breast Localization
Barry Rosen, M.D., FACS; Colleen M. Madden, M.D.
Monday, Nov. 29: 12:15 – 1:15pm CT
Contrast Enhanced Mammography: Implementation, Application and Biopsy (CME)
Ryan Gabriel, M.D.
Tuesday, Nov. 30: 8:00 – 9:00am CT
Advancing Clinical Excellence with ShearWave Elastography
Priyanka Grover, M.D.
Tuesday, Nov. 30: 12:15 – 1:15pm CT
A New Era of Breast Tomosynthesis: Using High-Resolution Imaging with 3DQuorum Technology
Stamatia V. Destounis, M.D., FACR, FSBI, FAIUM
Wednesday, Dec. 1: 12:15 – 1:15pm CT
For more information on Hologic’s RSNA 2021 offerings or to RSVP for a medical education session, please visit www.HologicVirtual.com.